The PPARα–leukotriene B4 pathway to inflammation control
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Inflammation is a local immune response to 'foreign' molecules, infection and injury. Leukotriene B4, a potent chemotactic agent that initiates, coordinates, sustains and amplifies the inflammatory response, is shown to be an activating ligand for the transcription factor PPARalpha. Because PPARalpha regulates the oxidative degradation of fatty acids and their derivatives, like this lipid mediator, a feedback mechanism is proposed that controls the duration of an inflammatory response and the clearance of leukotriene B4 in the liver. Thus PPARalpha offers a new route to the development of anti- or pro-inflammatory reagents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FFAs act as PPAR agonists facilitating translocation to the nucleus and dimerization to RXR [77,78].”
From Lipoprotein Lipase Regulates Microglial Lipid Droplet Accumulation (2021) · cites this paper as [77]
In the citing paper
“PPAR-α is involved in the regulation of pro-inflammatory genes, mainly by limiting cytokine expression.[109]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [109]
Citations
Cites
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects
Samuelsson, B., Dahlén, S.-E., Lindgren, J. Å., Rouzer, C. A., & Serhan, C. N. (1987) · Science · doi:10.1126/science.2820055 · Cited by 2,233
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Self-citationKliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., & Evans, R. M. (1992) · Nature · doi:10.1038/358771a0 · Cited by 1,741
Lee, S. S.-T., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., & Gonzalez, F. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3012 · Cited by 1,655
Self-citationKliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., & Evans, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7355 · Cited by 1,400
Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,376
Self-citation
Research works printed but not linked: 6
- Ford-Hutchinson, A. W. Crit. Rev. Immunol. 10, 1–11 (1990).
- Desvergne, B. & Wahli, W. in Inducible Transcription Vol. 1 (ed. Bæuerle, P.) 142–176 (Birkhäuser, Boston, 1995).
- Greene, M. E. et al. Gene Expr. 4, 281–299 (1995).
- Schmidt, A. et al. Mol. Endocrinol. 6, 1634–1641 (1992).
- Yu, K. et al. J. Biol. Chem. 270, 23975–23983 (1995). · DOI · Paper page
- Peters, J. M. et al. Mol. Pharmacol. 50, 67–94 (1996).
Cited by
Items 301–400 of 1,001
In Vivo Actions of Peroxisome Proliferator–Activated Receptors
Eldor, R., DeFronzo, R. A., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2003 · Cited by 126
den Broeder, M. J., Kopylova, V. A., Kamminga, L. M., & Legler, J. (2015) · PPAR Research · doi:10.1155/2015/358029 · Cited by 137
Eicosanoids in Cancer: New Roles in Immunoregulation
Johnson, A. M., Kleczko, E. K., & Nemenoff, R. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595498 · Cited by 124
“In particular, the role of PPARγ has been extensively studied in multiple types of cancer (Berger and Moller, 2002; Grommes et al., 2004; Panigrahy et al., 2005; Nemenoff, 2007; Roman, 2008).”
BackgroundInfluentialPeroxisome proliferator-activated receptors in cutaneous biology
Kuenzli, S., & Saurat, J. ‐. (2003) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2003.05532.x · Cited by 134
Ferguson, J. F., Allayee, H., Gerszten, R. E., Ideraabdullah, F., Kris-Etherton, P. M., Ordovás, J. M., Rimm, E. B., Wang, T. J., & Bennett, B. J. (2016) · Circulation: Cardiovascular Genetics · doi:10.1161/hcg.0000000000000030 · Cited by 123
Kornman, K. S. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.475s · Cited by 139
Raspé, E., Madsen, L., Lefebvre, A.-M., Leitersdorf, I., Gelman, L., Peinado-Onsurbe, J., Dallongeville, J., Fruchart, J.-C., Berge, R., & Staels, B. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32433-0 · Cited by 128
Narala, V. R., Adapala, R. K., Suresh, M. V., Brock, T. G., Peters-Golden, M., & Reddy, R. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.085118 · Cited by 126
The effects of dietary polyphenols on reproductive health and early development†
Ly, C., Yockell‐Lelièvre, J., Ferraro, Z. M., Arnason, J. T., Ferrier, J., & Gruslin, A. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu058 · Cited by 135
Teissier, E., Nohara, A., Chinetti, G., Paumelle, R., Cariou, B., Fruchart, J.-C., Brandes, R. P., Shah, A., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000150594.95988.45 · Cited by 110
“... in ROS was attributable to the induction of NADPH oxidase, because (1) preincubation with the NADPH oxidase inhibitor diphenyleneiodinium prevented the increase in ROS production; (2) PPAR- agonists increased O2 . production measured by superoxide dismutase–inhibitable cytochrome c reduction; (3) PPAR- agonists in…”
Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets
Peters-Golden, M., & Brock, T. G. (2001) · FEBS Letters · doi:10.1016/s0014-5793(00)02374-7 · Cited by 126
Edvardsson, U., Bergström, M., Alexandersson, M., Bamberg, K., Ljung, B., & Dahllöf, B. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33479-9 · Cited by 124
Regulation of apo A-I gene expression by fibrates
Staels, B., & Auwerx, J. H. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00313-4 · Cited by 124
Harnessing the anti-inflammatory potential of palmitoylethanolamide
Alhouayek, M., & Muccioli, G. G. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.007 · Cited by 128
Cyclooxygenase-2 in hepatocellular carcinoma
Wu, T. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.10.004 · Cited by 130
Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors
Clarke, S. D., Thuillier, P., Baillie, R., & Sha, X. (1999) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/70.4.566 · Cited by 137
The Role of Leukotriene B4 in Allergic Diseases
Ohnishi, H., Miyahara, N., & Gelfand, E. W. (2008) · Allergology International · doi:10.2332/allergolint.08-rai-0019 · Cited by 121
Akiyama, T. E., Nicol, C. J., Fievet, C., Staels, B., Ward, J. M., Auwerx, J., Lee, S. S. T., Gonzalez, F. J., & Peters, J. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107073200 · Cited by 121
Self-citationNitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation
Weinberg, J. B. (2000) · Immunologic Research · doi:10.1385/ir:22:2-3:319 · Cited by 121
Rodríguez-Calvo, R., Serrano, L., Coll, T., Moullan, N., Sánchez, R. M., Merlos, M., Palomer, X., Laguna, J. C., Michalik, L., Wahli, W., et al. (2008) · Diabetes · doi:10.2337/db08-0176 · Cited by 121
Self-citationTargeting PPAR receptors in the airway for the treatment of inflammatory lung disease
Belvisi, M. G., & Mitchell, J. A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00373.x · Cited by 127
“Interestingly, one of the early proposals regarding the mechanism of action of PPARa ligands was that they were antiinflammatory by affecting lipid mediator metabolism through regulating oxidative degradation of fatty acids (e.g. Leukotiene B4) (Devchand et al., 1996).”
BackgroundPPARs Mediate Lipid Signaling in Inflammation and Cancer
Michalik, L., & Wahli, W. (2008) · PPAR Research · doi:10.1155/2008/134059 · Cited by 117
“Many eicosanoids bind to PPARs and control tissue homeostasis and inflammation [3, 14].”
BackgroundSelf-citationSertznig, P., Seifert, M., Tilgen, W., & Reichrath, J. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20998 · Cited by 121
“F U N C T I O N O F P P A R S F O R P A T H O G E N E S I S 3 PPARa activation has been shown to reduce the duration of a LTB4or arachidonic acid-induced inflammatory response in the PPARa knockout mice (Devchand et al., 1996).”
BackgroundWestergaard, M., Henningsen, J., Rasmussen, S., Kristiansen, K., Johansen, C., Svendsen, M. L., Jensen, U. B., Schrøder, H. D., Staels, B., Iversen, L., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12536.x · Cited by 128
Diab, A., Hussain, R. Z., Lovett‐Racke, A. E., Chavis, J. A., Drew, P. D., & Racke, M. K. (2003) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.11.010 · Cited by 125
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118
“In line with these findings, PPARα knockout mice exhibit a prolonged inflammatory response compared with wild-type mice [ 38 ].”
ResultLeukotriene pathway genetics and pharmacogenetics in allergy
Duroudier, N. P., Tulah, A. S., & Sayers, I. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02015.x · Cited by 118
Eicosanoids and Their Drugs in Cardiovascular Diseases: Focus on Atherosclerosis and Stroke
Capra, V., Bäck, M., Barbieri, S. S., Camera, M., Tremoli, E., & Rovati, G. E. (2013) · Medicinal Research Reviews · doi:10.1002/med.21251 · Cited by 113
Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?
Rao, J. S., Lee, H.-J., Рапопорт, С. И., & Bazinet, R. P. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.31 · Cited by 137
Asthma and leukotrienes: antileukotrienes as novel anti‐asthmatic drugs
Claesson, H., & Se, D. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00418.x · Cited by 118
Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid
Kurihara, T. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02013-x · Cited by 117
Polyunsaturated fatty acids: From diet to binding to ppars and other nuclear receptors
Bordoni, A., Nunzio, M. D., Danesi, F., & Biagi, P. L. (2006) · Genes & Nutrition · doi:10.1007/bf02829951 · Cited by 130
The ketogenic diet; fatty acids, fatty acid-activated receptors and neurological disorders
Cullingford, T. E. (2004) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.09.008 · Cited by 124
Leukotrienes as Mediators of Asthma
NICOSIA, S., Capra, V., & Rovati, G. E. (2001) · Pulmonary Pharmacology & Therapeutics · doi:10.1006/pupt.2000.0262 · Cited by 116
Nuclear Receptors as New Perspective for the Management of Liver Diseases
Trauner, M., & Halilbasic, E. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.044 · Cited by 118
Genomics of metabolic adaptations in the peripartal cow
Loor, J. J. (2010) · animal · doi:10.1017/s1751731110000960 · Cited by 134
“Among the most potent PPARa endogenous ligands in non-ruminants are linoleic acid, linolenic acid and arachidonic acid derivates such as leukotriene B4 or prostaglandins D1 and D2 (Forman et al., 1995; Devchand et al., 1996).”
BackgroundThiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M. A., Mattison, D. R., Azoulay, L., & Krewski, D. (2018) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 112
“PPARa is involved in the regulation of lipid metabolism, fatty acid oxidation, glucose homeostasis, and inflammation (Devchand et al. 1996; Lehmann et al. 1997; Delerive et al. 2001; Zandbergen and Plutzky 2007).”
BackgroundMicroglial Corpse Clearance: Lessons From Macrophages
Márquez-Ropero, M., Benito, E., Plaza-Zabala, A., & Sierra, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00506 · Cited by 108
The role of the LTB4-BLT1 axis in health and disease
He, R., Chen, Y., & Cai, Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104857 · Cited by 127
DNA Binding-Independent Induction of I B Gene Transcription by PPAR
Delerive, P. (2002) · Molecular Endocrinology · doi:10.1210/me.16.5.1029 · Cited by 114
Ppars, metabolic disease and atherosclerosis
Fruchart, J., Staels, B., & Duriez, P. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0871 · Cited by 129
Brock, T. G., McNish, R. W., Bailie, M. B., & Peters-Golden, M. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.13.8276 · Cited by 114
Putative role of neuronal 5‐lipoxygenase in an aging brain
Manev, H., Uz, T., Sugaya, K., & Qu, T. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.10.1464 · Cited by 114
Cherkaoui‐Malki, M., Meyer, K., Wq, C., Latruffe, N., Yeldandi, A. V., Rao, M. S. R., Bradfield, C. A., & Reddy, J. K. (2001) · Gene Expression · doi:10.3727/000000001783992533 · Cited by 122
“For time course of induction, single dose of Wy-14,643 (250 flammation, and hepatocarcinogenesis (20,32,57,61, 67).”
BackgroundThe Role of PPAR Alpha in the Modulation of Innate Immunity
Grabacka, M., Pierzchalska, M., Plonka, P. M., & Pierzchalski, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910545 · Cited by 122
Parsing the Role of PPARs in Macrophage Processes
Toobian, D., Ghosh, P., & Katkar, G. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783780 · Cited by 120
“Interestingly, LTB4 and other fatty acid derived molecules are ligands for PPARa, thus this feedback loop promotes their own catabolism and leads to resolution of inflammation (69) (Figure 4).”
Background5-Lipoxygenase and atherosclerosis
Mehrabian, M., & Allayee, H. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200310000-00005 · Cited by 118
Cheng, S., Afif, H., Martel-Pelletier, J., Pelletier, J.-P., Li, X., Farrajota, K., Lavigne, M., & Fahmi, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402828200 · Cited by 112
Chinetti, G., Fruchart, J., & Staels, B. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802499 · Cited by 111
The biochemistry of oleate induction: Transcriptional upregulation and peroxisome proliferation
Gurvitz, A., & Rottensteiner, H. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.07.011 · Cited by 127
Costea, I., Mack, D. R., Lemaître, R. N., Israel, D. M., Marcil, V., Ahmad, A., & Amre, D. K. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.034 · Cited by 139
Wahli, W. (2002) · Swiss Medical Weekly · doi:10.4414/smw.2002.09939 · Cited by 109
Self-citationWoo, C.-H., You, H. J., Cho, S.-H., Eom, Y. W., Chun, J. S., Yoo, Y. J., & Kim, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104766200 · Cited by 110
Fauconnet, S., Lascombe, I., Chabannes, E., Adessi, G.-L., Desvergne, B., Wahli, W., & Bittard, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200172200 · Cited by 111
Self-citationLeukotriene receptors in atherosclerosis
Bäck, M., & Hansson, G. K. (2006) · Annals of Medicine · doi:10.1080/07853890600982737 · Cited by 109
Meissner, M., Stein, M., Urbich, C., Reisinger, K., Suske, G., Staels, B., Kaufmann, R., & Gille, J. (2004) · Circulation Research · doi:10.1161/01.res.0000113781.08139.81 · Cited by 109
Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?
Becker, J., Delayre‐Orthez, C., Frossard, N., & Pons, F. (2006) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2006.00425.x · Cited by 119
Wejksza, K., Lee-Chang, C., Bodogai, M., Bonzo, J. A., Gonzalez, F. J., Lehrmann, E., Becker, K. G., & Biragyn, A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201920 · Cited by 119
Self-citationJaradat, M., Wongsud, B., Phornchirasilp, S., Rangwala, S. M., Shams, G. E.-D. A. M., Sutton, M., Romstedt, K. J., Noonan, D. J., & Feller, D. R. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00822-x · Cited by 122
Bernardes, A., Souza, P. C. T., Muniz, J. R. C., Ricci, C. G., Ayers, S. D., Parekh, N., Godoy, A. S., Trivella, D. B. B., Reinach, P. S., Webb, P., et al. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.05.010 · Cited by 119
Emerging anti-inflammatory strategies for COPD
Cazzola, M., Page, C. P., Calzetta, L., & Matera, M. G. (2012) · European Respiratory Journal · doi:10.1183/09031936.00213711 · Cited by 109
Wang, P., Anderson, P. O., Chen, S., Paulsson, K. M., Sjögren, H. O., & Li, S. (2001) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00015-7 · Cited by 124
Roles of PPARs on regulating myocardial energy and lipid homeostasis
Yang, Q., & Li, Y. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0170-9 · Cited by 113
Lipoprotein Lipase Regulates Microglial Lipid Droplet Accumulation
Loving, B. A., Tang, M., Neal, M. C., Gorkhali, S., Murphy, R., Eckel, R. H., & Bruce, K. D. (2021) · Cells · doi:10.3390/cells10020198 · Cited by 105
A new class of obesity genes encodes leukocyte adhesion receptors
Dong, Z. M., Gutierrez-Ramos, J.-C., Coxon, A., Mayadas, T. N., & Wagner, D. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7526 · Cited by 105
Jiao, M., Ren, F. Z., Zhou, L., Zhang, X., Zhang, L., Wen, T., Wei, L., Wang, X., Shi, H., Bai, L., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.361 · Cited by 108
Chinetti, G., Fruchart, J.-C., & Staels, B. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200310000-00006 · Cited by 103
Role of Peroxisome Proliferator‐Activated Receptors in Inflammation Control
Youssef, J., & Badr, M. (2004) · BioMed Research International · doi:10.1155/s1110724304308065 · Cited by 103
Martin-McNulty, B., Tham, D. M., da Cunha, V., Ho, J. J., Wilson, D. W., Rutledge, J. C., Deng, G. G., Vergona, R. A., Sullivan, M. E., & Wang, Y.-X. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000085842.20866.6a · Cited by 103
Cancio, I., Ibabe, A., & Cajaraville, M. P. (1999) · Comparative Biochemistry and Physiology Part C Pharmacology Toxicology and Endocrinology · doi:10.1016/s0742-8413(99)00019-5 · Cited by 103
Salvadó, L., Barroso, E., Gómez-Foix, A. M., Palomer, X., Michalik, L., Wahli, W., & Vázquez‐Carrera, M. (2014) · Diabetologia · doi:10.1007/s00125-014-3331-8 · Cited by 105
Self-citationCorton, J. C., Fan, L.-Q., Brown, S. S., Anderson, S. P., Bocos, C., Cattley, R. C., Mode, A., & Gustafsson, J.-Α. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.3.463 · Cited by 102
“Mice that lack PPARa have a prolonged inflammatory response time after exposure to inflammatory mediators compared with wild-type mice (Devchand et al., 1996).”
BackgroundDefibrotide: Properties and clinical use of an old/new drug
Pescador, R., Capuzzi, L., Mantovani, M., Fulgenzi, A., & Ferrero, M. E. (2013) · Vascular Pharmacology · doi:10.1016/j.vph.2013.05.001 · Cited by 104
“…a concerted action of other mediators such as TXA2, LTB4 (a potent chemotactic agent that initiates, coordinates, sustains and amplifies the inflammatory response (Devchand et al., 1996)), CYSLT (Rossoni et al., 1996), PAF and activated complement products and histamine (Kubes and Ward, 2000).”
BackgroundInfluentialCombs, C. K., Bates, P., Karlo, J. C., & Landreth, G. E. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00052-3 · Cited by 108
Cuzzocrea, S., Mazzon, E., Paola, R. D., Peli, A., Bonato, A., Britti, D., Genovese, T., Muià, C., Crisafulli, C., & Caputi, A. P. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0605341 · Cited by 109
Klein, J. B., Buridi, A., Coxon, P. Y., Rane, M. J., Manning, T., Kettritz, R., & McLeish, K. R. (2001) · Cellular Signalling · doi:10.1016/s0898-6568(01)00151-6 · Cited by 101
Inoue, I., Noji, S., Awata, T., Takahashi, K., Nakajima, T., Sonoda, M., Komoda, T., & Katayama, S. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00249-5 · Cited by 100
Fenofibrate for patients with asymptomatic primary biliary cirrhosis
Dohmen, K., Mizuta, T., Nakamuta, M., Shimohashi, N., Ishibashi, H., & Yamamoto, K. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i6.894 · Cited by 99
Meertens, L. M., Miyata, K., Cechetto, J. D., Rachubinski, R. A., & Capone, J. P. (1998) · The EMBO Journal · doi:10.1093/emboj/17.23.6972 · Cited by 109
Gardner, O., Dewar, B. J., & Graves, L. M. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.012260 · Cited by 99
Central role of PPARα in the mechanism of action of hepatocarcinogenic peroxisome proliferators
Corton, J. C., Lapinskas, P. J., & Gonzalez, F. J. (2000) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(99)00232-8 · Cited by 107
Self-citationBesson, V. C., Chen, X. R., Plotkine, M., & Marchand‐Leroux, C. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.06.019 · Cited by 103
Beier, K., Völkl, A., & Fahimi, H. D. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00805-3 · Cited by 98
Kippenberger, S., Grundmann-Kollmann, M., Simon, S., Dang, T., Hardt‐Weinelt, K., Kaufmann, R., Bernd, A., & Loitsch, S. M. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01537.x · Cited by 100
Jha, P., Claudel, T., Baghdasaryan, A., Mueller, M., Halilbasic, E., Das, S. K., Lass, A., Zimmermann, R., Zechner, R., Hoefler, G., et al. (2014) · Hepatology · doi:10.1002/hep.26732 · Cited by 96
Keller, H., Devchand, P. R., Perroud, M., & Wahli, W. (1997) · Biological Chemistry · doi:10.1515/bchm.1997.378.7.651 · Cited by 98
Self-citationPPARα downregulates airway inflammation induced by lipopolysaccharide in the mouse
Delayre-Orthez, C., Becker, J., Guenon, I., Lagente, V., Auwerx, J., Frossard, N., & Pons, F. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-91 · Cited by 96
“Indeed, mice deficient in PPARα (PPARα -/- ) were reported to display an exacerbated reaction to various inflammatory stimuli, including LPS in the skin and the vessel [ 20-22 ].”
BackgroundPPARα Deficiency in Inflammatory Cells Suppresses Tumor Growth
Kaipainen, A., Kieran, M. W., Huang, S., Butterfield, C., Bielenberg, D. R., Mostoslavsky, G., Mulligan, R. C., Folkman, J., & Panigrahy, D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000260 · Cited by 98
“whereas PPARα deficient mice exhibit enhanced inflammation”
WY14,643, a PPARα Ligand, Has Profound Effects on Immune Responses In Vivo
Cunard, R., DiCampli, D., Archer, D. C., Stevenson, J. L., Ricote, M., Glass, C. K., & Kelly, C. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.6806 · Cited by 96
“PPAR is important in controlling the duration of in flammation induced by leukotriene B4 and arachidonic acid, and PPAR KO mice demonstrate a prolonged response to inflammatory stimuli ( 17 ).”
BackgroundNakshatri, H., & Bhat‐Nakshatri, P. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.10.2491 · Cited by 102
Nuclear Receptors in Bone Physiology and Diseases
Imai, Y., Youn, M.-Y., Inoue, K., Takada, I., Kouzmenko, A., & Kato, S. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2012 · Cited by 88
Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
Beggiato, S., Tomasini, M. C., & Ferraro, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00821 · Cited by 98
Marks, F., Müller‐Decker, K., & Fürstenberger, G. (2000) · Toxicology · doi:10.1016/s0300-483x(00)00301-2 · Cited by 107
Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis
Vosper, H., Khoudoli, G. A., Graham, T. L., & Palmer, C. N. A. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00232-2 · Cited by 104
Recent update on the PPARα-null mouse
Gonzalez, F. J. (1997) · Biochimie · doi:10.1016/s0300-9084(97)81506-4 · Cited by 95
Self-citationBarclay, T. B., Peters, J. M., Sewer, M. B., Ferrari, L., Gonzalez, F. J., & Morgan, E. T. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35029-3 · Cited by 94
Self-citationHepatic PPARα is critical in the metabolic adaptation to sepsis
Paumelle, R., Haas, J. T., Hennuyer, N., Baugé, E., Deleye, Y., Mesotten, D., Langouche, L., Vanhoutte, J., Cudejko, C., Wouters, K., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.037 · Cited by 99
Self-citationSugawara, A., Uruno, A., Kudo, M., Ikeda, Y., Sato, K., Taniyama, Y., Ito, S., & Takeuchi, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104560200 · Cited by 102
FoxO1 – the key for the pathogenesis and therapy of acne?
Melnik, B. C. (2010) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07344.x · Cited by 89
Eosinophils and cysteinyl leukotrienes
Bandeira‐Melo, C., & Weller, P. F. (2003) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(03)00074-7 · Cited by 100
Metadata
- Authors
- Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W.
- Affiliations
- University of Lausanne (CH)
- National Institutes of Health (US)
- Venue
- Nature
- Published
- 1996-11
- Volume
- 384
- Issue
- 6604
- Pages
- 39-43
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1671834350
- Cited by
- 1,345
- References
- 43
- Citations by year
- 2026: 3 · 2025: 17 · 2024: 14 · 2023: 21 · 2022: 9 · 2021: 38 · 2020: 30 · 2019: 23 · 2018: 21 · 2017: 24 · 2016: 23 · 2015: 22 · 2014: 43 · 2013: 34 · 2012: 49
- FWCI
- 28.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- PPARα, leukotriene B4, inflammation, transcription factor activation, fatty acid oxidation, lipid mediators, chemotaxis, anti-inflammatory agents, liver, feedback regulation
- MeSH terms
- Adaptation, Physiological, Animals, Cells, Cultured, Fatty Acids, Female, Gene Expression Regulation, HeLa Cells, Humans, Inflammation, Leukotriene B4, Ligands, Liver, Male, Oxidation-Reduction, Plasmids, Pyrimidines, Time Factors, Transcription Factors, Transfection, Chloramphenicol O-Acetyltransferase, Arachidonic Acid, Rats, Sprague-Dawley, Receptors, Cytoplasmic and Nuclear, Inflammation Mediators, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.